GHRS
GH Research Plc
NASDAQ · Healthcare · Biotechnology · IE
$18.28
+0.72%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.31
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.23
- EPS estimate
- -$0.29
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 9
- EPS misses (12Q)
- 2
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +6.4%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Strong Buy
- Price target
- $41
- PT range
- $39 – $44
- Analysts
- 4
4 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.29 | -$0.23 | Beat 19.58% | — |
| May 14, 2026 | -$0.27 | -$0.31 | Miss -14.81% | — |
| Mar 5, 2026 | -$0.29 | -$0.23 | Beat 20.69% | — |
| Nov 6, 2025 | -$0.23 | -$0.23 | In line | — |
| Aug 7, 2025 | -$0.22 | -$0.15 | Beat 31.82% | — |
| May 8, 2025 | -$0.61 | -$0.19 | Beat 68.85% | — |
| Feb 27, 2025 | -$0.23 | -$0.17 | Beat 26.09% | — |
| Nov 14, 2024 | -$0.25 | -$0.23 | Beat 8.00% | — |
| Sep 3, 2024 | -$0.24 | -$0.20 | Beat 16.67% | — |
| May 3, 2024 | -$0.22 | -$0.15 | Beat 31.82% | $80.0K |
| Feb 29, 2024 | -$0.20 | -$0.21 | Miss -5.00% | — |
| Nov 9, 2023 | -$0.20 | -$0.11 | Beat 45.00% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026